Skip to main content

XTLB · Xtl Biopharmaceuticals Ltd · Shareholders & Ownership

Track XTLB — free
$1.70 -0.03 (-1.45%) At close · Nov 4
Market Cap
$4.18M
Shares
2.46M
Volume · Nov 4 9546 Avg daily vol (3M) 8509

Every disclosed holder of XTLB in one list: 13F institutions, Schedule 13D and 13G filers, insiders (Forms 3, 4 and 5) and registered funds, each from its own latest filing. Holders nest by CIK and SEC reporting links, never by name, and each is summed once.

Who Owns XTLB

13F quarter Sep 30, 2026, combined view: filers that have not filed yet carry their Jun 30, 2026 positions

No chart: shares outstanding cannot be set against these holders.

Holder group Shares % Out
Institutional (13F) 9,789 —
Insiders (Forms 3, 4, 5) 0 —
13D/G-only blocks 0 —
Registered funds (N-PORT, not summed) 1,439 —

% Out is unavailable: a foreign private issuer reports ordinary shares, a different unit from the listed shares.

13D/G-only counts each filer's latest 13D or 13G that no 13F report of the listing contains, that names no 13F filer and that no counted insider files. Funds are never summed: their shares sit inside their advisers' 13F reports.

Holders of XTLB

# Holder Shares
1
RHUMBLINE ADVISERS
13F CIK 1115418 · Registered investment adviser · Jun 30, 2026
carried, not yet filed for the newest quarter
6,228
2
GAMMA Investing LLC
13F CIK 2010235 · Registered investment adviser · Sep 30, 2026
3,436
3
Fidelity Nasdaq Composite Index Fund
Fund S000055366 · Registered fund · Aug 31, 2026
Fidelity Concord Street Trust, not summed
1,439
4
UBS Group AG
13F CIK 1610520 · Bank · Jun 30, 2026
carried, not yet filed for the newest quarter
125

Shares are restated onto today's split basis. Change compares each row with the same holder's previous filing in the same source; a dash means there is none to compare. Nested 13D/G, insider and fund rows are not summed, since a 13F report already holds them.

Key facts CIK 1023549 CUSIP 98386D406 13F (30d) 1 filings 1 filers Visit website Investor relations